<DOC>
	<DOC>NCT00372775</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.</brief_summary>
	<brief_title>Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients with radiologically proven brain metastases secondary to nonsmall cell lung cancer Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic nonsmall cell lung cancer Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease. Brain metastases &gt;4 cm in any linear direction Intracranial or intratumoral hemorrhage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>brain metastases</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Phase 2</keyword>
</DOC>